Our study therefore aimed to investigate the effects of intensive debulking therapy on the outcomes of anti-CD19-CAR-T therapy in patients with R/R DLBCL with high tumor bulk. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.